{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-294634","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2025-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.154125+00:00","generated_at":"2026-05-16T17:04:36.817418+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share","bullets":["Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.","Concurrent private placement of 4,477,614 warrants at $0.335 exercise price; exercisable upon stockholder approval.","H.C. Wainwright placement agent gets 7.0% cash fee, 1.0% management fee, and 313,433 placement agent warrants at $0.4188.","Net proceeds for working capital and general corporate purposes.","30-day lock-up on equity issuances; one-year ban on Variable Rate Transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-294634","json":"https://secwatch.observer/filing/0001193125-25-294634.json","markdown":"https://secwatch.observer/filing/0001193125-25-294634.md","text":"https://secwatch.observer/filing/0001193125-25-294634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/fblg-20251124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:04:36.817418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"572d2f7bd590f4cbd7cc4ca81cda1d4b847004f0","claim":"FibroBiologics, Inc. issued to purchase up to 313,433 shares of Common Stock of warrant to Placement Agent (H.C. Wainwright & Co., LLC) for issued as compensation; exercise price $0.4188 per share.","evidence_excerpt":"Additionally, the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 313,433 shares of Common Stock), at an exercise price of $0.4188 per share (the “Placement Agent Warrants”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"to purchase up to 313,433 shares of Common Stock"},{"label":"Purchaser","value":"Placement Agent (H.C. Wainwright & Co., LLC)"},{"label":"Consideration","value":"issued as compensation; exercise price $0.4188 per share"}],"fact_type":"equity_issuance"},{"claim_id":"b7b8d2c2378fe1efa6fa5fd36a5e85d821014edd","claim":"FibroBiologics, Inc. issued to purchase 4,477,614 shares of Common Stock of warrant to institutional investors (the Purchasers) for exercise price $0.335 per share; no additional consideration at issuance.","evidence_excerpt":"4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.335 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchasers, in a concurrent private placement, warrants to","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"to purchase 4,477,614 shares of Common Stock"},{"label":"Purchaser","value":"institutional investors (the Purchasers)"},{"label":"Consideration","value":"exercise price $0.335 per share; no additional consideration at issuance"}],"fact_type":"equity_issuance"},{"claim_id":"94dd530933dcd0882154daf12510d2566f88e541","claim":"FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2025-11-24).","evidence_excerpt":"On November 24, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"approximately $1.5 million"},{"label":"Effective","value":"2025-11-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}